FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506800529> ?p ?o ?g. }

• W2506800529 endingPage "60154" @default.
• W2506800529 startingPage "60133" @default.
• W2506800529 abstract "Breast cancer is the disease with the highest impact on global health, being metastasis the main cause of death. To metastasize, carcinoma cells must reactivate a latent program called epithelial-mesenchymal transition (EMT), through which epithelial cancer cells acquire mesenchymal-like traits.Glypican-3 (GPC3), a proteoglycan involved in the regulation of proliferation and survival, has been associated with cancer. In this study we observed that the expression of GPC3 is opposite to the invasive/metastatic ability of Hs578T, MDA-MB231, ZR-75-1 and MCF-7 human breast cancer cell lines. GPC3 silencing activated growth, cell death resistance, migration, and invasive/metastatic capacity of MCF-7 cancer cells, while GPC3 overexpression inhibited these properties in MDA-MB231 tumor cell line. Moreover, silencing of GPC3 deepened the MCF-7 breast cancer cells mesenchymal characteristics, decreasing the expression of the epithelial marker E-Cadherin. On the other side, GPC3 overexpression induced the mesenchymal-epithelial transition (MET) of MDA-MB231 breast cancer cells, which re-expressed E-Cadherin and reduced the expression of vimentin and N-Cadherin. While GPC3 inhibited the canonical Wnt/β-Catenin pathway in the breast cancer cells, this inhibition did not have effect on E-Cadherin expression. We demonstrated that the transcriptional repressor of E-Cadherin - ZEB1 - is upregulated in GPC3 silenced MCF-7 cells, while it is downregulated when GPC3 was overexpressed in MDA-MB231 cells. We presented experimental evidences showing that GPC3 induces the E-Cadherin re-expression in MDA-MB231 cells through the downregulation of ZEB1.Our data indicate that GPC3 is an important regulator of EMT in breast cancer, and a potential target for procedures against breast cancer metastasis." @default.
• W2506800529 created "2016-08-23" @default.
• W2506800529 creator A5000443028 @default.
• W2506800529 creator A5041239672 @default.
• W2506800529 creator A5047323517 @default.
• W2506800529 creator A5047462387 @default.
• W2506800529 creator A5062018633 @default.
• W2506800529 creator A5070496596 @default.
• W2506800529 creator A5070832643 @default.
• W2506800529 creator A5073384022 @default.
• W2506800529 creator A5073523672 @default.
• W2506800529 creator A5075476037 @default.
• W2506800529 creator A5080246031 @default.
• W2506800529 date "2016-08-06" @default.
• W2506800529 modified "2023-10-14" @default.
• W2506800529 title "Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells" @default.
• W2506800529 cites W1597336200 @default.
• W2506800529 cites W1689351220 @default.
• W2506800529 cites W1808167613 @default.
• W2506800529 cites W1898755691 @default.
• W2506800529 cites W1963501822 @default.
• W2506800529 cites W1964847767 @default.
• W2506800529 cites W1965612162 @default.
• W2506800529 cites W1969825737 @default.
• W2506800529 cites W1972462861 @default.
• W2506800529 cites W1974338429 @default.
• W2506800529 cites W1974531415 @default.
• W2506800529 cites W1977543422 @default.
• W2506800529 cites W1978678628 @default.
• W2506800529 cites W1981521674 @default.
• W2506800529 cites W1986664280 @default.
• W2506800529 cites W1991713904 @default.
• W2506800529 cites W1997782804 @default.
• W2506800529 cites W2003252842 @default.
• W2506800529 cites W2013739993 @default.
• W2506800529 cites W2016360721 @default.
• W2506800529 cites W2019066381 @default.
• W2506800529 cites W2033979066 @default.
• W2506800529 cites W2035385440 @default.
• W2506800529 cites W2038869696 @default.
• W2506800529 cites W2051788298 @default.
• W2506800529 cites W2055159339 @default.
• W2506800529 cites W2060322741 @default.
• W2506800529 cites W2071635593 @default.
• W2506800529 cites W2076174220 @default.
• W2506800529 cites W2079080508 @default.
• W2506800529 cites W2105253426 @default.
• W2506800529 cites W2106285087 @default.
• W2506800529 cites W2106787323 @default.
• W2506800529 cites W2107261560 @default.
• W2506800529 cites W2116191527 @default.
• W2506800529 cites W2118195139 @default.
• W2506800529 cites W2118282497 @default.
• W2506800529 cites W2130487816 @default.
• W2506800529 cites W2134589440 @default.
• W2506800529 cites W2140551998 @default.
• W2506800529 cites W2140956181 @default.
• W2506800529 cites W2149533159 @default.
• W2506800529 cites W2169829977 @default.
• W2506800529 cites W2171380576 @default.
• W2506800529 cites W2173828584 @default.
• W2506800529 cites W2226761276 @default.
• W2506800529 cites W2312346791 @default.
• W2506800529 cites W2322558359 @default.
• W2506800529 cites W2417915442 @default.
• W2506800529 cites W318955610 @default.
• W2506800529 cites W4297745080 @default.
• W2506800529 cites W67531826 @default.
• W2506800529 doi "https://doi.org/10.18632/oncotarget.11107" @default.
• W2506800529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5312374" @default.
• W2506800529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27507057" @default.
• W2506800529 hasPublicationYear "2016" @default.
• W2506800529 type Work @default.
• W2506800529 sameAs 2506800529 @default.
• W2506800529 citedByCount "33" @default.
• W2506800529 countsByYear W25068005292017 @default.
• W2506800529 countsByYear W25068005292018 @default.
• W2506800529 countsByYear W25068005292019 @default.
• W2506800529 countsByYear W25068005292020 @default.
• W2506800529 countsByYear W25068005292021 @default.
• W2506800529 countsByYear W25068005292022 @default.
• W2506800529 countsByYear W25068005292023 @default.
• W2506800529 crossrefType "journal-article" @default.
• W2506800529 hasAuthorship W2506800529A5000443028 @default.
• W2506800529 hasAuthorship W2506800529A5041239672 @default.
• W2506800529 hasAuthorship W2506800529A5047323517 @default.
• W2506800529 hasAuthorship W2506800529A5047462387 @default.
• W2506800529 hasAuthorship W2506800529A5062018633 @default.
• W2506800529 hasAuthorship W2506800529A5070496596 @default.
• W2506800529 hasAuthorship W2506800529A5070832643 @default.
• W2506800529 hasAuthorship W2506800529A5073384022 @default.
• W2506800529 hasAuthorship W2506800529A5073523672 @default.
• W2506800529 hasAuthorship W2506800529A5075476037 @default.
• W2506800529 hasAuthorship W2506800529A5080246031 @default.
• W2506800529 hasBestOaLocation W25068005291 @default.
• W2506800529 hasConcept C104317684 @default.
• W2506800529 hasConcept C119056186 @default.
• W2506800529 hasConcept C121608353 @default.

• next